#INAVO120: Neue Hoffnung für Patientinnen mit #PIK3CA-mutiertem HR+/HER2- Brustkrebs! Auf dem #ASCO2025 stellte Prof. Sibylle Loibl die finale OS-Analyse vor: +7 Monate medianes Überleben mit #Inavolisib + #Palbociclib + #Fulvestrant in der First-Line-Therapie
www.docwirenews.com/post/shiftin...
NEW research summary from #ASCO25: Adding inavolisib to palbociclib and fulvestrant can help patients with PIK3CA-mutated, HR+, HER2- advanced #BreastCancer live longer: brnw.ch/21wT49i
#BCSM #INAVO120
Els resultats de l'assaig clínic de fase 3 #INAVO120 es presenten al congrés d'ASCO que se celebra a Chicago. La Dra. Cristina Saura, cap de la Unitat de Càncer de Mama de #VallHebron i investigadora principal del Grup de Càncer de Mama i Melanoma del @vhio.bsky.social és coautora de l'estudi.
Presented at #ASCO25 and published in @nejm.org , the results of the #INAVO120 — with Cristina Saura on the steering committee — show that inavolisib combined with standard therapy improves outcomes in PIK3CA-mutated advanced #BreastCancer
👉 https://linke.to/INAVO120ASCO25
@ascocancer.bsky.social
Over on that other site ❌, it was pointed out that this patient may be a candidate for #INAVO120, which is 💯 true (one of the limitations of social media space). Don’t forget to check 🩸 for PIK3CA in pts who recur early/on ET. (But, well—not a choice in our poll!)
1. Recent #FDA approvals:
a). #NATALEE: Adj #Ribociclib in HR+ Stg IIA - III, 400mg 3wks on, 1wk off for 3yrs. 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS
b). #INAVO120: Inavolisib + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ mBC. PFS 15.0 vs 7.3mos (HR 0.43)
2/5
#SABCS23 late breaking abstract to FDA approval: #Inavolisib based off #INAVO120 we 🗣️ design, findings, and AEs/management w/ Dr. Komal Jhaveri!
Full Discussion:
- Oncbrothers.com/inavo120
- Also on the “Oncology Brothers” podcast
#OncSky #MedSky #bcsm #BreastCancer #SABCS24
